We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+24.19%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$136M
AUM Growth
+$21.9M
Cap. Flow
-$8.36M
Cap. Flow %
-6.13%
Top 10 Hldgs %
68.06%
Holding
58
New
8
Increased
12
Reduced
7
Closed
22

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$1.34M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$1.29M
3
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$943K
4
KIN
Kindred Biosciences, Inc.
KIN
+$596K
5
DGX icon
Quest Diagnostics
DGX
+$593K

Top Sells

Rank Stock Value
1
GIVN
GIVEN IMAGING LTD
GIVN
+$2.57M
2
HUM icon
Humana
HUM
+$1.87M
3
SLTM
SOLTA MED INC (DE)
SLTM
+$1.85M
4
AGN
Allergan plc
AGN
+$1.8M
5
ELV icon
Elevance Health
ELV
+$1.25M

Sector Composition

Rank Sector Weight
1 Miscellaneous 61.3%
2 Healthcare 38.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VXRT
26
DELISTED
Vaxart
VXRT
$857K 0.63%
18,604
+2,129
+13% +$93.7K
SUPN icon
27
CALL
Supernus Pharmaceuticals
SUPN
$2.57B
$754K 0.55%
100,000
-200,000
-67% -$1.4M
ZGNX
28
DELISTED
Zogenix, Inc.
ZGNX
$607K 0.45%
22,042
-12,500
-36% -$280K
FOLD
29
DELISTED
Amicus Therapeutics
FOLD
$588K 0.43%
250,000
+115,000
+85% +$252K
RIGL icon
30
Rigel Pharmaceuticals
RIGL
$875M
$570K 0.42%
+20,000
New +$587K
KIN
31
DELISTED
Kindred Biosciences, Inc.
KIN
$559K 0.41%
+50,000
New +$596K
CRTX
32
CALL
DELISTED
CORNERSTONE THERAPEUTICS INC
CRTX
$475K 0.35%
50,000
-150,000
-75% -$1.42M
XNPT
33
DELISTED
XENOPORT, INC.
XNPT
$443K 0.33%
+77,000
New +$417K
VIRX
34
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$394K 0.29%
396
– –
CYTK icon
35
Cytokinetics
CYTK
$10.8B
$368K 0.27%
56,666
– –
STML
36
DELISTED
Stemline Therapeutics, Inc.
STML
$323K 0.24%
16,464
– –
AORT icon
37
Artivion
AORT
$1.3B
– –
-118,288
Closed -$1.11M
ELV icon
38
Elevance Health
ELV
$86.6B
– –
-15,000
Closed -$1.25M
GYRE icon
39
Gyre Therapeutics
GYRE
$708M
– –
-257
Closed -$1.08M
HUM icon
40
Humana
HUM
$47.1B
– –
-20,000
Closed -$1.87M
LLY icon
41
CALL
Eli Lilly
LLY
$1.05T
– –
-50,000
Closed -$2.52M
LLY icon
42
PUT
Eli Lilly
LLY
$1.05T
– –
-50,000
Closed -$2.52M
MRK icon
43
CALL
Merck
MRK
$369B
– –
-131,000
Closed -$5.95M
NBIX icon
44
Neurocrine Biosciences
NBIX
$15.8B
– –
-50,000
Closed -$566K
PCRX icon
45
Pacira BioSciences
PCRX
$1.03B
– –
-20,500
Closed -$986K
TCRT icon
46
Alaunos Therapeutics
TCRT
$4.22M
– –
-667
Closed -$394K
AGN
47
DELISTED
Allergan plc
AGN
– –
-12,524
Closed -$1.8M
ACHN
48
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-100,000
Closed -$302K
MDCO
49
CALL
DELISTED
Medicines Co
MDCO
– –
-25,000
Closed -$838K
IPXL
50
CALL
DELISTED
Impax Laboratories, Inc.
IPXL
– –
-96,900
Closed -$1.98M
1
2
3

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q4 2013 Portfolio in Review

As of Q4 2013, Healthcare Value Capital held 58 positions worth $136M, up 19% from $114M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Healthcare Value Capital withdrew a net $8.36M in Q4 2013, closing 22 positions and reducing 7 holdings. Its most notable exit was GIVEN IMAGING LTD, an estimated $2.57M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 61% of assets, up from 57% a quarter earlier, followed by Healthcare.

Against the trend, Healthcare Value Capital opened a new position in Baxter International worth $1.39M.

  • Healthcare Value Capital's largest Q4 2013 buy was Baxter International: 36,820 shares worth $1.39M.
  • Healthcare Value Capital added most to Supernus Pharmaceuticals in Q4 2013, an estimated $1.29M increase.
  • Healthcare Value Capital's biggest Q4 2013 reduction was ANI Pharmaceuticals, cutting an estimated $890K.
  • Healthcare Value Capital fully exited GIVEN IMAGING LTD in Q4 2013, selling an estimated $2.57M.
  • Healthcare Value Capital's ten largest holdings make up 68% of its $136M portfolio in Q4 2013.
  • Healthcare Value Capital opened 8 new positions and closed 22 in Q4 2013.
  • Healthcare Value Capital's portfolio value rose 19% quarter-over-quarter to $136M.

Based on Healthcare Value Capital's 13F filing for Q4 2013, filed 13 Feb 2014.